Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience August 23, 2023
Two programmes evaluating CD47-blocking fusion protein evorpacept for patients with haematologic malignancies discontinued August 23, 2023
Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer August 23, 2023
WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC August 23, 2023
First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy Announced August 23, 2023
Data Highlighting Clinical Efficacy & Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in “Cancer Discovery” August 23, 2023
FDA Filing Acceptance and Priority Review for TIBSOVO in the Treatment of IDH1-mutated R/R MDS announced August 23, 2023
Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 23, 2023
